CRWD vs PFE: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
CrowdStrike Holdings, Inc. · Technology
$436.32
+34.6% upside to fair value
Grade B
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
CRWD has more upside to fair value
(+34.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
PFE |
| Current Price |
$436.32 |
$26.33 |
| Fair Value Estimate |
$587.16 |
$33.85 |
| Upside to Fair Value |
+34.6%
|
+28.6%
|
| Market Cap |
$110.7B |
$149.8B |
| Forward P/E |
-601.6x
|
19.3x
|
| EV / EBITDA |
951.5x
|
12.9x
|
| Price / Sales |
23.0x
|
2.4x
|
| Price / FCF |
89.3x
|
16.5x
|
| Revenue Growth YoY |
+23.3%
|
-1.2%
|
| Gross Margin |
74.9%
|
70.3%
|
| Operating Margin |
-5.4%
|
24.7%
|
| Return on Equity |
-4.7%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.12%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
CrowdStrike Holdings, Inc. is a leading cybersecurity company specializing in cloud-based endpoint protection and threat intelligence, with a dominant subscription revenue model accounting for over 95% of total revenue. The business quality is medium due to strong revenue growth of 23.3% in the most recent quarter and a robust earnings growth of 141.9% in the same period, supported by a high gros…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
CRWD |
PFE |
| Zone Low |
$440.37 |
$25.39 |
| Zone High |
$499.09 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|